Small molecule · Antagonist of CXCR4 chemokine receptor (CXCR4) · developed by Genzyme
Plerixafor is a small-molecule inhibitor of the CXCR4 chemokine receptor that blocks binding of its ligand SDF-1α, which otherwise anchors hematopoietic stem cells in the bone marrow. By disrupting this interaction, it mobilizes hematopoietic stem cells into the peripheral blood, and it is studied in diffuse large B-cell lymphoma.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Nov 19, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02570542 | Phase 2 | Diffuse Large B-cell Lymphoma (DLBCL) | Active not recruiting | SNY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Diffuse Large B-cell Lymphoma (DLBCL)Refractory Diffuse Large B-cell Lymphoma (DLBCL)Relapsed Diffuse Large B-cell Lymphoma (DLBCL)
Updated Nov 8, 2026. Something wrong or missing? Report it on the SNY page.
See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SNY catalysts and pipeline →